 SOUTH SAN FRANCISCO, Calif., May 01, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced final results from Phase 1 and Phase 1b studies of its small molecule LRRK2 inhibitor, BIIB122DNL151, which is being developed in collaboration with Biogen as a potential treatment of Parkinsons disease. Safety and biomarker goals were met in both studies, supporting plans to advance BIIB122DNL151 into late-stage clinical development in Parkinsons disease by year-end 2021. The results will be presented at the International Association of Parkinsonism and Related Disorders Virtual Congress, being held May 1-4. 